Therapeutics News and Research

RSS
'Conflict of Interest and Scientific Discovery' symposium to be held at Penn’s Perelman School of Medicine

'Conflict of Interest and Scientific Discovery' symposium to be held at Penn’s Perelman School of Medicine

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Main culprit of Alzheimer's disease causes memory loss

Main culprit of Alzheimer's disease causes memory loss

Study sheds light on genetic differences between colorectal cancer in older and younger patients

Study sheds light on genetic differences between colorectal cancer in older and younger patients

Global market for asthma treatment expected to reach $21.7 billion by 2020

Global market for asthma treatment expected to reach $21.7 billion by 2020

DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen creates catalog of qualified tools and reagents to advance basic discoveries in biology

Amgen creates catalog of qualified tools and reagents to advance basic discoveries in biology

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics reports financial results for first quarter 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.